Cancer Immunotherapy

Immune Privilege in the Eye Can Be Bypassed Successfully

Published in Cancer Weekly, November 22nd, 1999

Tumor-specific, cytotoxic T lymphocyte (CTL)-mediated immunotherapy can bypass the immune privileged status of the anterior chamber of the eye and successfully prevent and eradicate tumors.

Luc R.H.M Schurmans and colleagues from Leiden University Medical Center, The Netherlands, and Loyola University of Chicago, Illinois, USA, sought to establish to what extent immune privilege interferes with T-cell-mediated antitumor immunotherapy.

They established a new ocular tumor model in the mouse and tested whether well-defined tumor-specific CTLs could eradicate an immunogenic intraocularly growing tumor ("Successful Immunotherapy of an Intraocular Tumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry